Abilify - instructions for use of the drug, structure, Contraindications

1,284 5 minutes read

Abilify - instructions for use of the drug, structure, Contraindications

Abilifay is a neuroleptic drug.

Abilifai: indications and dosage

Abilify is used in the treatment of patients with seizures (sharp) Schizophrenia. The drug can also be used for maintenance treatment in people with schizophrenia..

Abilify tablets may be recommended for the treatment of acute forms of manic episodes., developed in bipolar disorder type 1.

Abilify can also be used as a maintenance treatment for bipolar I disorder after a mixed or manic episode..

Abilify is taken orally, regardless of food. Due to possible memory impairment, it is recommended to monitor the patient's intake of Abilify.

Dosage is determined depending on the nature of the disease., comorbidities and ongoing therapy. Patients, who are more 65 years, as well as patients with impaired liver and kidney function, dose adjustment is not required..

Abilifai: Dosing in schizophrenia

Abilify is prescribed in the initial amount 10-15 mg / day (are taking aripiprazole 1 once a day). supportive (medium) dose – 15 mg / day. Dose may be adjusted by your doctor, clinical trials have confirmed the efficacy of aripiprazole in the dose range 10-30 mg / day.

Abilifai: Dosing for Manic Episodes in Bipolar Disorders

Abilify is prescribed in the initial dose 15-30 mg / day (are taking aripiprazole 1 once a day). Dose changes can be made at intervals of 24 hours. Dose may be titrated by a doctor, studies have confirmed efficacy within doses 15-30 mg / day with a course of administration lasting 3-12 weeks. Efficacy and safety of doses above 30 mg/day not evaluated in clinical studies.

If in patients with bipolar disorder type 1, as well as mixed episodes or manic episodes in the background 6 weekly course of taking Abilify (15-30 mg / day) no symptoms noted, such maintenance therapy is considered effective. It is necessary to periodically conduct diagnostics to determine the feasibility of further maintenance therapy..

Abilifai: overdose

Aripiprazole studies have information on single dose 1080 mg, which was accompanied by the development of an overdose and had a favorable outcome.

When intoxicated with aripiprazole, patients developed drowsiness, vomiting, weakness and diarrhea. Patients, who were hospitalized due to an overdose of Abilify, no ECG changes noted, laboratory and physiological parameters.

In post-marketing studies, cases of admission by adult patients up to 450 mg aripiprazole, followed by tachycardia. In children with an overdose (single dose up to 195 mg) potentially dangerous effects develop, including loss of consciousness and extrapyramidal symptoms.

Treatment of an overdose of the drug Abilify includes symptomatic agents, support activities (including ensuring normal airway patency, IVL, oxygenation).

In the treatment of overdose, it is necessary to take into account clinical symptoms and monitor the function of the cardiovascular system with ECG recording. (for timely detection of rhythm disturbances).

The use of sorbents (in particular activated carbon) within an hour after taking the tablets, Abilify orally reduces the peak levels of aripiprazole and AUC by 41% and 51% respectively.

The efficacy of hemodialysis in aripiprazole intoxication has not been studied., but theoretically (taking into account the degree of association with albumins and the nature of excretion) hemodialysis does not lead to a significant decrease in serum levels of this drug.

Abilifai: side effects

On the part of the immune system: anaphylaxis
From the side of the blood, lymphatic system: leukopenia, thrombocytopenia
From the nervous system, psyche: dizziness, hallucinations, confusion, cognitive decline, tremor, excitation, ataxia, psychotic symptoms, convulsions, dysarthria, coma, encephalopathy
From the gastrointestinal tract: vomiting, abdominal discomfort, diarrhea
The respiratory system: breathlessness
From the Hepatobiliary system: reversible increase in liver function tests, hepatitis
From the side of the skin, subcutaneous tissues: skin rashes, photosensitivity, angioedema, hives, itch
From the side of the kidneys, urinary system: renal dysfunction, acute kidney failure, pain in the kidneys, the formation of acyclovir precipitates in the tubules of the kidneys
Other: gemoliticheskaya anemia, microangiopathy, thrombocytopenia in immunocompromised patients

Abilifai: Contraindications

During therapy with Abilify tablets, such an undesirable effect on:

SSS: tachycardia or bradycardia, gipotenziya (including orthostatic), atrioventrikulyarnaya blockade, ischemia of the heart muscle, phlebitis, extrasystole, palpitations, QT interval prolongation, hemorrhage, heart failure, deep vein thrombosis, Atrial fibrillation, cardiac arrest. In rare cases,: loss of consciousness, golovnogo ischemia mozga, auricular flutter, vasovagal syndrome, tromboflebit.
GI: change in appetite, difficulty weight management, caries, flatulence, gastritis, gastroenteritis, hastroэzofahealnыy reflux, gingivitis, gastrointestinal bleeding, hemorrhoids, anal sphincter weakness, colitis, stomatitis, ulceration of mucous membranes, oral candidiasis, belching, swelling of the tongue, fekaloma, cholelithiasis, cholecystitis, vomiting, violations of the Chair. In rare cases,: increased activity of ALT and AST, pancreatitis, esophagitis, vomiting blood, krovotochivosty right, cheilitis, perforation of the wall of the digestive tract, enlargement of the liver, hepatitis.
Musculoskeletal system: raʙdomioliz, increased activity of creatine phosphokinase, rheumatoid arthritis, Tendinitis, arthritis, tendobursitis, myopathy, myalgia, muscular weakness, muscle cramps and twitches, pain in bones and joints.
CNS: extrapyramidal states, dizziness, impaired psychomotor activity, nervousness, depression, tremor, hyperptyalism, manic and suicidal thoughts, gait disturbance, confusion, hostility, insomnia, akathisia, drowsiness. In rare cases,: hallucinations, buccoglossal syndrome, euphoria, reduced reflexes, intrusive thoughts, dystonia, neuroleptic malignant syndrome, paresthesia, decreased memory and concentration, changes in libido, stupor, amnesia, hyperactivity, panic reactions. Besides, Possible restless leg syndrome, depersonalization, hyperreflexia, myoclonus, increased sensitivity to stimuli.
respiratory system: breathlessness, bronchospasm, nose bleed, laringit, Ikotech, pneumonia. In rare cases,: coughing up blood, increased sputum production, inhalation pneumonia, dryness of the nasal mucosa, gipoksiya, pulmonary embolism, respiratory failure, pulmonary edema, apnea.
Senses: ear pain, conjunctivitis, lacrimation, change in taste, otitis, Cataract, sore eyes, frequent blinking, deafness, eye hemorrhage, diplopia, tinnitus, photophobia.
genitourinary system: leykoreya, voiding, hematuria, cystitis, urinary retention, amenorrhea, dizurija, vaginal bleeding, premature ejaculation, candidiasis, menorragija, stones in the kidneys, renal failure, polyuria, nocturia, urinary incontinence. In rare cases,: cervicitis, breast pain, anorgazmija, galactorrhea, burning in the external genital area, painful erection, gynecomastia, glikozuriâ, urolithiasis disease.

Allergic reactions: hives, maculopapular rash, eczema, exfoliative dermatitis, itch, hyperhidrosis, xerosis, baldness, acne, vesiculobullous rash, seborrhea, psoriasis, anaphylaxis, angioedema.

Other negative phenomena: impotence, flu-like symptoms, neck and chest pain, tightness in the throat, abdominal distention, weakness, jaw stiffness, headache, pain in the pelvic area, peripheral edema, swelling of the face, tension in the chest. Besides, hyperglycemia or hypoglycemia are possible, hyperlipidemia, giperʙiliruʙinemija, giperkreatininemiя, hyperuricemia, hypercholesterolemia, increase or decrease in serum potassium and sodium levels, obtaining an acid urine sample.

Gout has also been reported, cyanosis, Dehydration, thirst, iron deficiency anemia, Obesity.

Separate negative phenomena on the background of therapy:

Suicidal attempts:

Suicidal thoughts and suicide attempts are common in psychotic patients., when treating such patients, it is recommended to use the minimum dose of aripiprazole and monitor the patient's condition and behavior. Drug therapy should be carried out simultaneously with psychotherapy.

Pozdnyaya dyskinesia:

With an increase in the duration of antipsychotic therapy, the risk of tardive dyskinesia increases.. If symptoms of this condition appear, it is necessary to reduce the dose of aripiprazole or stop taking it.. After discontinuation of the drug Abilify, there is a possibility of an increase in signs of tardive dyskinesia, in some patients, symptoms appear for the first time after discontinuation of Abilify tablets.

neuroleptic malignant syndrome:

Patients, treated with neuroleptics, including aripiprazole, described cases of neuroleptic malignant syndrome, accompanied by muscle stiffness, mental disorders, hyperpyrexia, irregular blood pressure and pulse, as well as sweating, rhabdomyolysis, acute kidney failure and increased activity of creatinine phosphokinase. If the patient has symptoms of neuroleptic malignant syndrome, it is necessary to stop taking antipsychotics.

Giperglikemiâ:

Patients, treated with atypical antipsychotics, in some cases, hyperglycemia developed (which may be associated with ketoacidosis) and giperosmolyarnaya coma (sometimes with fatal consequences). A direct relationship between treatment with atypical antipsychotics and glycemic type disorder has not been clearly established., however, patients, who have been diagnosed with diabetes, should monitor glucose levels. The need for glucose control also applies to people at risk of diabetes..

Clinical studies of the drug Abilify in pregnant women have not been conducted.. Careful risk-benefit assessment should be carried out if aripiprazole is needed in pregnant women..

In animal studies, aripiprazole was determined in the milk of rats., no similar studies have been performed in humans.. Abilify should not be given to breastfeeding women..

Abilifai: interactions with other drugs and alcohol

Famotidine does not significantly affect the pharmacokinetic profile of aripiprazole.

Strong CYP2 D6 and CYP3 A4 inhibitors decreased aripiprazole clearance in studies. If necessary, the combined use of Abilify with inhibitors of these isoenzymes requires correction (reduction) doses of aripiprazole.

Abilify does not lead to a significant change in the pharmacokinetics of CYP2 D6 and CYP3 A4 substrates. In the course of studies, aripiprazole did not displace warfarin from protein binding.

Alcohol is contraindicated during drug treatment.

Abilifai: composition and properties

Active material:

5 mg or 10 mg or 15 mg or 30 mg aripiprazole.

Auxiliary components:

For all dosages: corn starch, lactose monohydrate, magnesium stearate, hydroksypropyltsellyuloza, microcrystalline cellulose.

Besides, to:

tablets 5 mg - aluminum blue lacquer
tablets 10 mg 30 mg - iron oxide red
Pill 15 mg - iron oxide yellow

Product form:

Abilify tablets, labeled, appropriate dosage, by 7 pieces in aluminum laminated blister packs, in a cardboard box 4 blister plates.

Storage conditions:

Abilify must be stored in places, to which children do not have access, at room temperature.

Abilifai tablets are suitable 3 years after release.

Abilifai: general information

Sales form: on prescription
Farm. Group: Antipsychotic drugs (neuroleptics)

Vladimir Andreevich Didenko

1,284 5 minutes read